[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fk48qH7A00nmsH7yUQu9TyHN6Ubrx-a8464Rhnb_I0zs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"Hospital Mutua de Terrassa",[4],33,false,8,0,18011,29,[13,16,19,22,25,27,29,31],{"name":14,"count":15},"Celiac Disease",6,{"name":17,"count":18},"Crohn Disease",3,{"name":20,"count":21},"Microscopic Colitis",2,{"name":23,"count":24},"Prolapse; Female",1,{"name":26,"count":24},"Prolapse Genital",{"name":28,"count":24},"Prolapse Uterovaginal",{"name":30,"count":24},"Diabetes Mellitus, Type I",{"name":32,"count":24},"Pregestational Diabetes",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,70,88,106,133,151,179,197,225],{"intervention":43,"totalTrials":24,"cells":44},"100cc of 2% ropivacaine",{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":51,"PHASE4":53,"NA":68},{"trials":46,"activeCount":9},[],{"trials":48,"activeCount":9},[],{"trials":50,"activeCount":9},[],{"trials":52,"activeCount":9},[],{"trials":54,"activeCount":9},[55],{"nctId":56,"briefTitle":57,"status":58,"phases":59,"primaryCompletion":60,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":65},"NCT03513276","Effect of Local Infiltration Anesthesia in a Hip Arthroplasty Fast Track Program.","COMPLETED",[39],"2018-02","2016-02",63,[64],"Hip Osteoarthritis",[43,66,67],"Saline Solution","Adrenaline 10mcg\u002Fml",{"trials":69,"activeCount":9},[],{"intervention":66,"totalTrials":24,"cells":71},{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":86},{"trials":73,"activeCount":9},[],{"trials":75,"activeCount":9},[],{"trials":77,"activeCount":9},[],{"trials":79,"activeCount":9},[],{"trials":81,"activeCount":9},[82],{"nctId":56,"briefTitle":57,"status":58,"phases":83,"primaryCompletion":60,"completion":60,"start":61,"enrollment":62,"conditions":84,"interventions":85},[39],[64],[43,66,67],{"trials":87,"activeCount":9},[],{"intervention":67,"totalTrials":24,"cells":89},{"EARLY_PHASE1":90,"PHASE1":92,"PHASE2":94,"PHASE3":96,"PHASE4":98,"NA":104},{"trials":91,"activeCount":9},[],{"trials":93,"activeCount":9},[],{"trials":95,"activeCount":9},[],{"trials":97,"activeCount":9},[],{"trials":99,"activeCount":9},[100],{"nctId":56,"briefTitle":57,"status":58,"phases":101,"primaryCompletion":60,"completion":60,"start":61,"enrollment":62,"conditions":102,"interventions":103},[39],[64],[43,66,67],{"trials":105,"activeCount":9},[],{"intervention":107,"totalTrials":24,"cells":108},"levofloxacin",{"EARLY_PHASE1":109,"PHASE1":111,"PHASE2":113,"PHASE3":115,"PHASE4":117,"NA":131},{"trials":110,"activeCount":9},[],{"trials":112,"activeCount":9},[],{"trials":114,"activeCount":9},[],{"trials":116,"activeCount":9},[],{"trials":118,"activeCount":9},[119],{"nctId":120,"briefTitle":121,"status":122,"phases":123,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":129},"NCT00429975","Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia","TERMINATED",[39],"2005-09","2004-08",45,[128],"Pneumonia, Pneumococcal",[107,130],"ceftriaxone",{"trials":132,"activeCount":9},[],{"intervention":130,"totalTrials":24,"cells":134},{"EARLY_PHASE1":135,"PHASE1":137,"PHASE2":139,"PHASE3":141,"PHASE4":143,"NA":149},{"trials":136,"activeCount":9},[],{"trials":138,"activeCount":9},[],{"trials":140,"activeCount":9},[],{"trials":142,"activeCount":9},[],{"trials":144,"activeCount":9},[145],{"nctId":120,"briefTitle":121,"status":122,"phases":146,"completion":124,"start":125,"enrollment":126,"conditions":147,"interventions":148},[39],[128],[107,130],{"trials":150,"activeCount":9},[],{"intervention":152,"totalTrials":24,"cells":153},"Dabigatran",{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":160,"PHASE4":162,"NA":164},{"trials":155,"activeCount":9},[],{"trials":157,"activeCount":9},[],{"trials":159,"activeCount":9},[],{"trials":161,"activeCount":9},[],{"trials":163,"activeCount":9},[],{"trials":165,"activeCount":9},[166],{"nctId":167,"briefTitle":168,"status":169,"phases":170,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":177},"NCT02742480","Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY)","UNKNOWN",[],"2019-06","2019-12","2016-06-28",500,[176],"Cardioembolic Stroke",[152,178],"Acenocoumarol",{"intervention":178,"totalTrials":24,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":189,"NA":191},{"trials":182,"activeCount":9},[],{"trials":184,"activeCount":9},[],{"trials":186,"activeCount":9},[],{"trials":188,"activeCount":9},[],{"trials":190,"activeCount":9},[],{"trials":192,"activeCount":9},[193],{"nctId":167,"briefTitle":168,"status":169,"phases":194,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":195,"interventions":196},[],[176],[152,178],{"intervention":198,"totalTrials":24,"cells":199},"Assess the effectiveness and safety of DAAs in patients with IBD.",{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":208,"NA":210},{"trials":201,"activeCount":9},[],{"trials":203,"activeCount":9},[],{"trials":205,"activeCount":9},[],{"trials":207,"activeCount":9},[],{"trials":209,"activeCount":9},[],{"trials":211,"activeCount":9},[212],{"nctId":213,"briefTitle":214,"status":58,"phases":215,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":223},"NCT05452187","Evaluation of the Safety and Effectiveness of Direct-acting Antiviral Drugs in the Treatment of Hepatitis C in Patients With Inflammatory Bowel Disease: National Multicenter Study",[],"2021-07-30","2021-12-20","2021-03-12",79,[221,222],"Inflammatory Bowel Diseases","Hepatitis C Virus Infection",[198,224],"Evaluate the interaction of DAAs with IBD drugs, particularly immunosuppressants and\u002For biologics.",{"intervention":224,"totalTrials":24,"cells":226},{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":235,"NA":237},{"trials":228,"activeCount":9},[],{"trials":230,"activeCount":9},[],{"trials":232,"activeCount":9},[],{"trials":234,"activeCount":9},[],{"trials":236,"activeCount":9},[],{"trials":238,"activeCount":9},[239],{"nctId":213,"briefTitle":214,"status":58,"phases":240,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":241,"interventions":242},[],[221,222],[198,224]]